Drug Research

University of Oxford and Novo Nordisk announced a landmark research collaboration focused on type 2 diabetes. The partnership will enable scientists from Novo Nordisk and University of Oxford to collaborate to discover innovative approaches for treating type 2 diabetes....

H. Lundbeck A/S is collaborating with IBM's Watson Health to accelerate the development of innovative medicines to treat psychiatric and neurological disorders. The collaboration will combine Lundbeck's expertise in the treatment of psychiatric and neurological disorders...

PharmAthene, Inc. and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, announced the signing of a definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. Altimmune's current investors include Novartis Venture...

Evotec AG announced it has entered into an integrated drug discovery collaboration on an ion channel target with Asahi Kasei Pharma Corporation, a wholly owned subsidiary of Asahi Kasei Corporation, Tokyo, Japan. Under the terms of...

Maverick Therapeutics Inc , an MPM Capital portfolio company, and Takeda Pharmaceutical Company Limited announced that they have entered a collaboration to develop Maverick’s T-cell engagement platform created specifically to improve the utility of T-cell redirection therapy for the...

Takeda Pharmaceutical Company Limited and PvP Biologics, Inc announced a global agreement for the development of KumaMax, a novel enzyme designed to break down the immune-reactive parts of gluten in the stomach, thereby avoiding the painful symptoms and damage...

Marinus Pharmaceuticals Inc , a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders announced that the U.S. FDA has granted Orphan Drug Designation to its CNS-selective GABAA modulator, ganaxolone, for the treatment...